A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors

Targeting angiogenesis is a valid anti-cancer strategy. Aflibercept is designed to sequester circulating vascular endothelial growth factor (VEGF) by preventing VEGF from binding to its receptors. This phase I study was to evaluate a new formulation of subcutaneously administered aflibercept in pati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Wang-Gillam, Andrea, Tew, William P., Rothenberg, Mace L., Dupont, Jakob, Cooper, Wendy, Sternas, Lars, Buzenet, Giliane, Sosman, Jeffrey A., Spriggs, David R., Lockhart, Albert Craig
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2011
Assuntos:
Phase I Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3432791/
https://ncbi.nlm.nih.gov/pubmed/22002018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-011-9753-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados